Table 3 Summary of epigenetic targeted therapy, and immunomodulatory agents and ongoing clinical trials in NKTCL patients
From: Novel target and treatment agents for natural killer/T-cell lymphoma
Agent | Target | Trial ID | Number of estimated enrollment | Study phase | Combined agents | Indication | Results for NKTCL | References | |
|---|---|---|---|---|---|---|---|---|---|
Immuno-modulatory agent | Thalidomide | / | NCT02085655 | 264 | 3 | P-Gemox or methotrexate, dexamethasone | Previously untreated or r/r NKTCL | / | / |
Epigenetic targeted agents | Chidamide | HDACi | NCT03820596 | 37 | 1/2 | Sintilimab | r/r ENKTL | CR:59.5% PR:48.6% 1.5yPFS:52.5% 1.5y OS:76.2% | [120] |
Chidamide | HDACi | NCT03630731 | 32 | 2 | / | Chemotherapy responded stage IV or r/r NKTCL | / | / | |
Chidamide | HDACi | NCT04414969 | 35 | 2 | Anti PD-1 antibody, Pegaspargase | Stage IE and IIE ENKTL | / | / | |
Chidamide | HDACi | NCT04994210 | 30 | 2 | Sintilimab | Newly diagnosed ENKTL | / | / | |
Chidamide | HDACi | NCT02878278 | 24 | 2 | / | r/r NKTCL | CR: 33% | [118] | |
Vorinostat | HDACi | NCT00336063 | 18 | 1 | Azacitidine | Nasal NKTCL | / | / | |
Romidepsin | HDACi | NCT01913119 | 16 | 1 | / | r/r NKTCL | / | / | |